Remibrutinib for Hidradenitis Suppurativa
What You Need to Know Before You Apply
What is the purpose of this trial?
This study aims to better understand how Bruton's tyrosine kinase (BTK) inhibition with remibrutinib works in hidradenitis suppurativa (HS), a complex inflammatory disease with different types of lesions.
Are You a Good Fit for This Trial?
This trial is for adults aged 18–65 who have had hidradenitis suppurativa (HS) for at least 6 months, with at least 5 abscesses or inflamed lumps in at least two different body areas, and at least one chronic draining lesion.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Remibrutinib
Trial Overview
The study compares remibrutinib (LOU064), a drug that blocks BTK, to a placebo. It aims to see how the drug affects tissue changes in people with moderate to severe HS. Participants are randomly assigned to receive either the drug or placebo.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Participants will receive remibrutinib during treatment period.
Participants will receive matching placebo during treatment period.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.